Portola Pharmaceuticals Annual Revenue, Competitors, Number of Employees and Funding

Claim your profile

Overview

Location:
Total Funding:$772M
Industry:Pharma
Founded:2003
Lead Investor(s):Morgan Stanley, Citigroup
Press
Claim your profile

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Portola Pharmaceuticals's estimated annual revenue is currently $24M per year.
  • Portola Pharmaceuticals received $345.0M in venture funding in September 2017.
  • Portola Pharmaceuticals's estimated revenue per employee is $52,288
  • Portola Pharmaceuticals's total funding is $772M.

Employee Data

  • Portola Pharmaceuticals has 459 Employees.
  • Portola Pharmaceuticals grew their employee count by 9% last year.
  • Portola Pharmaceuticals currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Trifecta Clinic...
$13.1M653%N/A
DURECT Corporat...
N/A120N/AN/A
Rancho BioScien...
$10.9M5423%N/A
ApotheCom
$45.2M225N/AN/A
Tlc Pharmacy
$8.6M435%N/A
Otsuka America
$11.5M5719%N/A
endpoint Clinic...
$59.7M29710%N/A
GCAM
$19.1M954%N/A
VistaGen Therap...
N/A16N/AN/A
Pliant Therapeu...
$10.9M5417%N/A
Missing a competitor? Contribute!?
Submit

We are dedicated to discovering, developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. The company's two FDA approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.

keywords:Biotechnology,Healthcare,Pharmaceuticals

459

Number of Employees

$24M

Revenue (est)

1

Current Jobs

9%

Employee Growth %

$772M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Mardi DierCfoEmail Available
Ernie MeyerExecutive Vice President and Chief Human Resources OfficerEmail Available
John CurnutteExecutive Vice President Of Research & Development
Evan SusserSenior Director, Qa, Product Quality And Gxp ComplianceEmail Available
Alpana LoombaDirector, Clinical OperationsEmail Available
Charlotte FureyDirector, Clinical Data ManagementEmail Available
Justin LawrenceIt ManagerEmail Available
Ravi Kumar MonangiSenior Director, ItEmail Available
Vikas KawatraSenior Vice President Of Information TechnologyEmail Available
William PrettoDirector, Sales OperationsEmail Available

Portola Pharmaceuticals News

09/03/2019 - Portola Pharmaceuticals Announces Proposed Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced plans to offer, ...

09/08/2019 - Portola Pharmaceuticals Announces Pricing of Public Offering ...

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing ...

09/03/2019 - Portola -4.8% alongside $200M share offering

Portola Pharmaceuticals (NASDAQ:PTLA) is down 4.8% after filing to offer $200M in common shares. The prospectus comes via Goldman ...

Portola Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2003-12-09$21.0MAMultipleArticle
2005-01-19$21.0MASutter Hill Ventures, Prospect VenturesArticle
2005-11-09$46.0MBAdvanced Technology VenturesArticle
2006-10-18$20.0MUndisclosedHercules Technology Growth CapArticle
2007-05-08$70.0MCMultipleArticle
2008-07-10$60.0MUndisclosedMultipleArticle
2011-11-22$89.0MUndsiclosedTemasekArticle
2014-10-06$185.4MUndisclosedMorgan StanleyArticle
2015-03-11$100.0MUndisclosedMorgan StanleyArticle
2017-09-13$345.0MUndisclosedMorgan StanleyArticle

Portola Pharmaceuticals Executive Hires

DateNameTitleReference
2006-08-30Mardi DierCFOArticle
2008-06-25Bill LisVP Biz Development/Commercial OperatioArticle
2009-09-25William LisCOOArticle
2010-03-12Charles HomcyCo-ChairmanArticle
2017-11-07John LawrenceSVP Product Development & Chief Medical OfficerArticle
2018-03-13John MoriartyEVP & General counselArticle
2018-06-26Glenn Bramesenior vice president of technical operationsArticle
2018-08-10Ernie MeyerEVP & Chief Human Resources OfficerArticle
2019-01-29Sheldon KoenigEVP & Chief Commercial OfficerArticle